TWI826463B - 稠合噻吩化合物 - Google Patents

稠合噻吩化合物 Download PDF

Info

Publication number
TWI826463B
TWI826463B TW108120511A TW108120511A TWI826463B TW I826463 B TWI826463 B TW I826463B TW 108120511 A TW108120511 A TW 108120511A TW 108120511 A TW108120511 A TW 108120511A TW I826463 B TWI826463 B TW I826463B
Authority
TW
Taiwan
Prior art keywords
group
compound
alkyl
pharmaceutically acceptable
mmol
Prior art date
Application number
TW108120511A
Other languages
English (en)
Chinese (zh)
Other versions
TW202000674A (zh
Inventor
凱爾 W H 程
阿帕瑞吉塔 荷斯可特 克瑞西亞
保羅 E 艾德曼
黎 方
法蘭克 默庫里歐
羅伯特 蘇利文
Original Assignee
美商拜歐斯瑞克斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商拜歐斯瑞克斯公司 filed Critical 美商拜歐斯瑞克斯公司
Publication of TW202000674A publication Critical patent/TW202000674A/zh
Application granted granted Critical
Publication of TWI826463B publication Critical patent/TWI826463B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW108120511A 2018-06-13 2019-06-13 稠合噻吩化合物 TWI826463B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862684495P 2018-06-13 2018-06-13
US62/684,495 2018-06-13

Publications (2)

Publication Number Publication Date
TW202000674A TW202000674A (zh) 2020-01-01
TWI826463B true TWI826463B (zh) 2023-12-21

Family

ID=67263033

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108120511A TWI826463B (zh) 2018-06-13 2019-06-13 稠合噻吩化合物

Country Status (8)

Country Link
US (2) US11191769B2 (https=)
EP (1) EP3807283A1 (https=)
JP (1) JP7365059B2 (https=)
CN (1) CN112601751B (https=)
AU (1) AU2019284605A1 (https=)
CA (1) CA3101335C (https=)
TW (1) TWI826463B (https=)
WO (1) WO2019241271A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2020387392B2 (en) 2019-11-19 2025-09-11 Bristol-Myers Squibb Company Compounds useful as inhibitors of Helios protein
WO2021155050A1 (en) * 2020-01-29 2021-08-05 Biotheryx, Inc. Kinase modulators, pharmaceutical compositions, and therapeutic applications
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
WO2022061348A1 (en) 2020-09-16 2022-03-24 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN116583509A (zh) * 2020-10-07 2023-08-11 上海睿跃生物科技有限公司 治疗癌症的化合物和方法
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
TW202237580A (zh) 2020-12-14 2022-10-01 美商拜歐斯瑞克斯公司 Pde4降解劑、醫藥組合物及治療應用
JP2024504932A (ja) 2021-01-13 2024-02-02 モンテ ローザ セラピューティクス， インコーポレイテッド イソインドリノン化合物
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila
WO2023069731A1 (en) * 2021-10-22 2023-04-27 Monte Rosa Therapeutics, Inc. Compounds that mediate protein degradation and methods of use thereof
US12419962B2 (en) 2022-03-16 2025-09-23 Biotheryx, Inc. Quinazolines, pharmaceutical compositions, and therapeutic applications
WO2024015855A1 (en) 2022-07-13 2024-01-18 Monte Rosa Therapeutics, Inc. COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS
CN120303264A (zh) 2022-09-09 2025-07-11 医诺康治疗公司 CK1α和双重CK1α/GSPT1降解化合物
WO2024222918A1 (zh) * 2023-04-28 2024-10-31 中国药科大学 一种苯并六元杂环类gspt1蛋白降解剂及其应用
CN119371398A (zh) * 2023-07-25 2025-01-28 安道麦阿甘有限公司 用于制备噻吩酮的新路线
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964842A1 (en) * 2005-09-27 2008-09-03 Tian Jin Hemay Bio-Tech Co., Ltd. 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR
EP2093228B1 (en) * 2006-11-15 2012-02-22 Tianjin Hemay Bio-Tech Co., Ltd. Pyrroline-2-one derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof
WO2016191178A1 (en) * 2015-05-22 2016-12-01 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
TWI756957B (zh) * 2016-12-21 2022-03-01 美商拜歐斯瑞克斯公司 靶向蛋白質之化合物、組合物、方法及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170042598A (ko) 2014-08-22 2017-04-19 셀진 코포레이션 항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1964842A1 (en) * 2005-09-27 2008-09-03 Tian Jin Hemay Bio-Tech Co., Ltd. 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR
EP2093228B1 (en) * 2006-11-15 2012-02-22 Tianjin Hemay Bio-Tech Co., Ltd. Pyrroline-2-one derivatives against cell releasing tumor necrosis factor, preparation methods and uses thereof
WO2016191178A1 (en) * 2015-05-22 2016-12-01 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
TWI756957B (zh) * 2016-12-21 2022-03-01 美商拜歐斯瑞克斯公司 靶向蛋白質之化合物、組合物、方法及其用途

Also Published As

Publication number Publication date
CN112601751B (zh) 2024-04-02
US20220088025A1 (en) 2022-03-24
EP3807283A1 (en) 2021-04-21
JP2021527098A (ja) 2021-10-11
WO2019241271A1 (en) 2019-12-19
CA3101335C (en) 2024-01-09
TW202000674A (zh) 2020-01-01
AU2019284605A1 (en) 2020-12-10
CN112601751A (zh) 2021-04-02
US11191769B2 (en) 2021-12-07
US20200000814A1 (en) 2020-01-02
JP7365059B2 (ja) 2023-10-19
CA3101335A1 (en) 2019-12-19

Similar Documents

Publication Publication Date Title
TWI826463B (zh) 稠合噻吩化合物
US11400084B2 (en) Aminoamide compounds
US10889593B2 (en) Compounds targeting proteins, compositions, methods, and uses thereof
US10562917B2 (en) Chimeric compounds targeting proteins, compositions, methods, and uses thereof
US11236103B2 (en) Bifunctional compounds
US11352338B2 (en) Substituted isoindolinones
US10584133B2 (en) Thienopyrimidinone compounds
WO2019173224A1 (en) Deuterated compounds and chimeras and uses thereof

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees